含奈达铂与含顺铂联合化疗方案治疗晚期卵巢癌的临床对比研究  

Clinical comparative study of combination chemotherapy regimen containing nedaplatin with containing cisplatin in patients with advanced ovarian cancer.

作　　者：衣翠华[1] 张昕[1] 侯明[1] 张文东[1] 黎莉[1] 郝静[1] 王秀问[1] 

机构地区：[1]山东大学齐鲁医院肿瘤防治研究中心,济南250012

出　　处：《现代妇产科进展》2006年第5期336-339,共4页Progress in Obstetrics and Gynecology

摘　　要：目的:比较含奈达铂与含顺铂联合化疗方案治疗晚期卵巢癌的疗效和不良反应。方法:2003年1月至2005年6月收治晚期卵巢癌患者37例,分别进入奈达铂+环磷酰胺或顺铂+环磷酰胺组,分析两组的近期疗效及毒副作用。结果:奈达铂组与顺铂组的近期有效率分别为41.18%和56.25%,两组无统计学差异(0.5>P>0.25);奈达铂组血液学毒性的发生率高于顺铂组,III度+IV度粒细胞减少、血小板减少尤为明显(发生率分别为65.0%vs 52.9%,15.0%vs 5.9%),但无统计学意义(P>0.25);奈达铂组与顺铂组胃肠道反应总体发生率近似,但III度+IV度胃肠道反应发生率前者低于后者,分别为20.0%和41.2%(0.25>P>0.1);奈达铂组2例患者(10%)出现肝功能损害,顺铂组未发现肝功能损害。两组均未出现肾功能损害病例。血β2-MG异常两组间也相似,但顺铂组尿β2-MG异常显著高于奈达铂组,并有统计学意义(P<0.025)。结论:奈达铂+环磷酰胺为晚期卵巢癌的有效化疗方案,近期疗效接近顺铂+环磷酰胺;奈达铂组的毒副作用以骨髓抑制为主,少数患者出现肝功能损害;顺铂组的毒副作用以胃肠道反应及早期肾功能异常为主。Objective：To compare the efficacies and side-effects of combination chemo- therapy regimen containing nedaplatin with containing cisplatin in patients with advanced ovarian cancer. Methods： From Jan. 2003 to June 2005,37 patients with advanced ovarian cancer were given chemotherapy, nedaplatin ＋ cyclophosphamide or cisplatin ＋ cyclophosphamide. The efficacies and side-effects were compared between the two groups. Results：The response rates were 41.18% vs 56.25% in the nedaplatin group vs cisplatin group, there was no statistical difference between them. Myelosuppression in the nedaplatin group was severer than that in the cisplatin group, while gastrointestinal toxicity was weaker, especially 3 to 4-grade toxicity, but there were all no statistical differences. Hepatic toxicity appeared in two patients in the nedaplatin group, while no hepatic toxicity appeared in the cisplatin group;Serum β2-microglobulin elevation were the same in the two groups, while urine β2-microglobulin elevation was more often in the cisplatin group than that in the nedaplatin group, and there was statistical difference between them （ P 〈 0.025 ）. Conclusion： Nedaplatin ＋ cyclophosphamide is an effective regimen for patients with advanced ovarian cancer, its efficacy is similar to that of cisplatin ＋ cyclophos phamide. The main side-effect of nedaplatin ＋ cyclophosphamide is myelosuppression, while that of cisplatin ＋ cyclophosphamide are gastrointestinal toxicity and nephrotoxicity. Other toxicities are rare.

关 键 词：卵巢肿瘤 奈达铂 顺铂 联合化疗 

分 类 号：R737.31[医药卫生—肿瘤]